Ian Critchley - Spero Therapeutics Head Microbiology
| SPRO Stock | USD 1.55 0.01 0.64% |
Insider
Ian Critchley is Head Microbiology of Spero Therapeutics
| Address | 675 Massachusetts Avenue, Cambridge, MA, United States, 02139 |
| Phone | 857 242 1600 |
| Web | https://sperotherapeutics.com |
Spero Therapeutics Management Efficiency
The company has return on total asset (ROA) of 0.109 % which means that it generated a profit of $0.109 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.2495 %, meaning that it created $0.2495 on every $100 dollars invested by stockholders. Spero Therapeutics' management efficiency ratios could be used to measure how well Spero Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 21st of May 2024, Return On Tangible Assets is likely to grow to 0.13. Also, Return On Capital Employed is likely to grow to 0.14. At this time, Spero Therapeutics' Non Current Assets Total are very stable compared to the past year. As of the 21st of May 2024, Other Current Assets is likely to grow to about 4.7 M, while Total Assets are likely to drop about 119.9 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Christopher Ogden | CytomX Therapeutics | 40 | |
| Oleg Nodelman | Nuvation Bio | 44 | |
| Adam Zlotnick | Assembly Biosciences | N/A | |
| Hoyoung MD | CytomX Therapeutics | 55 | |
| Bronson Crouch | Instil Bio | 51 | |
| Michael MSBA | NextCure | 63 | |
| Robert Bazemore | Nuvation Bio | 53 | |
| Tharaknath Rao | Assembly Biosciences | N/A | |
| Kathryn Falberg | Nuvation Bio | 60 | |
| Karl MD | Achilles Therapeutics PLC | 57 | |
| Mark Dudley | Instil Bio | N/A | |
| FMEDSCI MD | Achilles Therapeutics PLC | 49 | |
| W Vernon | Nuvation Bio | 65 | |
| Jamie Moore | CytomX Therapeutics | N/A | |
| David MD | Nuvation Bio | 54 | |
| Kim Blickenstaff | Nuvation Bio | 68 | |
| Kerry Wentworth | Nuvation Bio | 51 | |
| Robert Coutts | Achilles Therapeutics PLC | 40 | |
| Stacy Markel | Nuvation Bio | 59 | |
| Michele Anderson | Assembly Biosciences | N/A | |
| Dr IV | Assembly Biosciences | 52 | |
Management Performance
| Return On Equity | 0.25 | ||||
| Return On Asset | 0.11 |
Spero Therapeutics Leadership Team
Elected by the shareholders, the Spero Therapeutics' board of directors comprises two types of representatives: Spero Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Spero. The board's role is to monitor Spero Therapeutics' management team and ensure that shareholders' interests are well served. Spero Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Spero Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Satyavrat CFA, CFO Treasurer | ||
| James Brady, Chief Officer | ||
| Ted Jenkins, VP Relations | ||
| Ian Critchley, Head Microbiology | ||
| Susannah Walpole, Head Operations | ||
| Esther Rajavelu, CFO Officer | ||
| Timothy Keutzer, Senior Vice President - Development | ||
| Angela MD, VP Devel | ||
| MBA MD, President, CoFounder | ||
| Tamara LLM, Chief Secretary |
Spero Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Spero Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.25 | ||||
| Return On Asset | 0.11 | ||||
| Profit Margin | 0.22 % | ||||
| Operating Margin | 0.69 % | ||||
| Current Valuation | 16.48 M | ||||
| Shares Outstanding | 53.99 M | ||||
| Shares Owned By Insiders | 20.16 % | ||||
| Shares Owned By Institutions | 25.92 % | ||||
| Number Of Shares Shorted | 468.05 K | ||||
| Price To Earning | 81.20 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out World Market Map to better understand how to build diversified portfolios, which includes a position in Spero Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Spero Stock, please use our How to Invest in Spero Therapeutics guide.You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for Spero Stock analysis
When running Spero Therapeutics' price analysis, check to measure Spero Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Spero Therapeutics is operating at the current time. Most of Spero Therapeutics' value examination focuses on studying past and present price action to predict the probability of Spero Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Spero Therapeutics' price. Additionally, you may evaluate how the addition of Spero Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |
Is Spero Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Spero Therapeutics. If investors know Spero will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Spero Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.753 | Earnings Share 0.43 | Revenue Per Share 1.969 | Quarterly Revenue Growth 0.55 | Return On Assets 0.109 |
The market value of Spero Therapeutics is measured differently than its book value, which is the value of Spero that is recorded on the company's balance sheet. Investors also form their own opinion of Spero Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Spero Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Spero Therapeutics' market value can be influenced by many factors that don't directly affect Spero Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Spero Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Spero Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Spero Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.